Clinical trial NCT02632487: Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults
Official title: Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: American Heart Association
First posted: 2015-12-16
Enrollment: 58
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study will evaluate the feasibility and efficacy of combining a traditional, structured exercise intervention with an innovative intervention designed to decrease sedentary behavior and increase non-exercise physical activity (NEPA).

Detailed description: A recruitment of 40 sedentary men and women ≥ 60 years of age with elevated cardiovascular risk and follow them for 20 weeks. Participants will be randomly assigned (n = 20/group) to 1) an 8-week, twice-weekly, multi-modal, center-based exercise intervention (EX) followed by 12 additional weeks of follow-up assessment, or 2) the same intervention with participants also asked to wear a validated lightweight activity tracker on their hip during waking hours and instructed on how to reduce sedentary behavior increase NEPA within their daily routines (EX + NEPA). Evaluations will be done to 1) the extent to which EX + NEPA modifies sedentary behavior, 2) the impact of the interventions on cardiovascular risk factors, including blood pressure, exercise capacity, waist circumference, and circulating biomarkers, and 3) develop and optimize study procedures to guide the future trial.

Eligibility criteria: Inclusion Criteria:

* Sedentary lifestyle, defined as \<150 min/wk of moderate physical activity by CHAMPS questionnaire
* Moderate to high-risk of CHD events according to ATP-III risk classification algorithm
* Willingness to be randomized to either intervention group
* Willingness to participate in all study procedures

Exclusion Criteria:

* Failure to provide informed consent;
* Regular participation in an exercise training program within the last 3 months
* Absolute contraindication(s) to exercise training (American College of Sports Medicine guidelines)
* Office SBP \> 180 mm Hg or DBP \> 110 mm Hg
* Severe cardiac disease, i.e. NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
* Myocardial infarction or stroke within past year
* Significant cognitive impairment, i.e. known dementia or a Mini-Mental State Examination score \< 24
* Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis, ALS;
* Severe rheumatologic/orthopedic disease, e.g., awaiting joint replacement, active inflammatory disease
* Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen;
* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;
* Other significant co-morbid conditions that would impair ability to participate in the intervention
* Simultaneous participation in another intervention trial

Primary outcomes:
measure: Blood pressure between the groups
timeFrame: 20 weeks
Secondary outcomes:
measure: Exercise capacity between the groups
timeFrame: 20 weeks
measure: Waist circumference between the groups
timeFrame: 20 weeks
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: UF Clinical Translational Research Building
state: Florida
Study officials:
affiliation: Univesity of Florida
name: Stephen Anton
role: PRINCIPAL_INVESTIGATOR
References: